Agency added that it is advising seniors to first consult with their doctors to determine if the vaccine is right for them<\/p>\n<\/h3>\n
By Physician\u2019s Briefing Staff HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, June 29, 2023 (HealthDay News) — Americans ages 60 and up can get their vaccine for respiratory syncytial virus (RSV) this fall, the U.S. Centers for Disease Control and Prevention has announced.<\/p>\n
On Thursday, Rochelle Walensky, M.D., the outgoing CDC director, gave her signature to a recommendation made last week by an advisory panel of outside experts for a single dose of the vaccines made by Pfizer and GlaxoSmithKline. The U.S. Food and Drug Administration sanctioned the shots last month for adults 60 and older. The CDC added in a statement<\/a> that it is advising seniors to first consult with their doctors to determine if the vaccine is right for them.<\/p>\n While some, including Robert Blancato, executive director of the National Association of Nutrition and Aging Services Programs, wanted the CDC to give a stronger vaccine recommendation for those ages 65 and up, the advisory panel offered the weaker endorsement after raising questions, the Associated Press<\/em> reported. Those included how well the vaccine worked in those who were most frail, whether there might be a need for boosters and costs.<\/p>\n Pfizer has not revealed their pricing plan. GSK plans to charge between $200 and $295 a shot.<\/p>\n RSV can appear like the common cold, but can be dangerous for infants, children and the elderly, the AP<\/em> reported. Those adults considered most at risk have chronic heart or lung disease, a weakened immune system, or live in a long-term care facility.<\/p>\n